Navigation Links
Shareholder Alert: Pomerantz Law Firm has filed a Class Action Against Biolase, Inc. and Certain Officers - BIOL
Date:8/26/2013

NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Biolase, Inc.  ("Biolase" or the "Company") (NASDAQ: BIOL) and certain of its officers.  The class action, filed in United States District Court, Central District of California, and docketed under SACV 13-1317-DMG, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Biolase between November 5, 2012 and August 7, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Biolase securities during the Class Period, you have until October 22, 2013 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Biolase is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was facing near term solvency issues; (ii) the Company faced severe liquidity problems; (iii) the Company's sales were not as strong as reported; and (iv) as a result of the foregoing, the Company's financial statements were false and misleading at all relevant times.

On August 9, 2013, the Company announced in its quarterly report for the period ending June 30, 2013, that Biolase was in breach if its financial covenants related to its lines of credit.  On this news, shares of Biolase declined $1.61 per share, more than 47%, to close at 1.81 per share on August 13, 2013.

Then on August 14, 2013, an analyst report was published on seekingalpha.com which criticized the Company for misleading investors regarding the extent of its solvency problems as well as providing the market with false guidance regarding the Company's sales and the state of adoption of the Company's products by practitioners.  On this news, shares of Biolase declined $0.61 per share, more than 33%, to close at 1.20 per share on August 14, 2013.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
rswilloughby@pomlaw.com


'/>"/>
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
2. Concord Medical Announces Acquisition of Its Shares by CEO and COO from Other Shareholders
3. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
4. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
5. Teamsters Protest McKessons Worker Abuse And Executive Pay At Shareholder Meeting
6. Alliquas CEO Issues Midyear Corporate Update for Shareholders
7. Sinovac Schedules 2013 Annual Meeting of Shareholders
8. Millenia Hope, Inc. Updates to Shareholders
9. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
10. CVBT Shareholders Vote for Change
11. Cytos Invites to the Annual Shareholders Meeting 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... The global emerging cancer diagnostics market is ... 2016 to 2023 and reach a figure of $6.34 ... a chronic disease and is affecting a huge population. ... This report is focused on emerging cancer diagnostics market ... propelled due to factors such as: increasing number of ...
(Date:3/28/2017)... 28, 2017  Medeon Biodesign, Inc., a ... pleased to announce that the Company led and ... Orthopedics, Inc., a San Jose, CA ... for orthopedic extremity applications.  The ... primarily due to procedure volume growth, lifestyle influences ...
(Date:3/28/2017)... 28, 2017  "US Cancer Generics Market Outlook ... indicators and trend analysis related to the emergence ... pharmaceutical market in US. The report analyzes various ... on cancer generics drugs in recent years. The ... billions of dollars for various stake holders involved ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor from ... rubber bands used in conjunction with my braces always rubbed against the inside ... way to prevent this problem." The O.B.S. was the result of his brainstorming. ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... in many scientific laboratories. The assembly protocols involve many repetitive steps and often ... for automation, which enables the high-throughput needed, and results in a lower error ...
(Date:3/29/2017)... Hollywood, CA (PRWEB) , ... March 29, 2017 , ... ... Northridge , is now offering laser dental treatments. Dental lasers are safe and ... Laser dentistry expands patients’ options and can improve the overall quality of care. , ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/29/2017)... ... 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is pleased ... Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with ... S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint ...
Breaking Medicine News(10 mins):